KR840006342A - 복소환식 화합물 및 그 제법 - Google Patents
복소환식 화합물 및 그 제법 Download PDFInfo
- Publication number
- KR840006342A KR840006342A KR1019830005071A KR830005071A KR840006342A KR 840006342 A KR840006342 A KR 840006342A KR 1019830005071 A KR1019830005071 A KR 1019830005071A KR 830005071 A KR830005071 A KR 830005071A KR 840006342 A KR840006342 A KR 840006342A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- atom
- group
- compound
- general formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
- C07C205/26—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups and being further substituted by halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (30)
- 다음의 일반식을 갖는 복소환식 화합물과 의학적으로 무방한 그의 염, 수화물 및 용매화합물,상기식에서 R은 수소원자, 또는 C1-6알킬, 치환되었거나 비치환된 아미디노, 치환되었거나 비치환된 구아니디노, 또는 -(C1-6알킬렌)x 기 (이때 x는 0 또는 1이고, R1과 R2는 독립적으로 수소원자나 또는 C1-6알킬기이고, 또는는 5- 또는 6-원환의 복소환상기로서 N원자에 추가하여 -NH--O- 또는 -S- 결합을 함유할 수 있다)이고 ; X와 Y는 독립적으로 -NH-, -O-또는 -S-결합을 나타내고 ; m은 0 또는 1이고 ; Z는기[이때 W는 -NH- 또는 -CH2- 결합이고, Q는 =NH, , =N-CN, =CH-NO2, =N-SO2NH2, =N-CONH2, =NSO2(아릴), =NSO2(C1-6알킬) 또는 =N-(C1-6알킬)기이고, R3와 R4는 각각 수소원자, C1-6알킬, C2-6알케닐 또는 C2-6알킬기이고, 또는는 5- 또는 6-원환의 복소환상기로서 N 원자이외에 -NH-, -O- 또는 -S- 결합을 포함할수 있다.]가[이때 G는 =CH 또는 =N- 결합이고, R5는 수소원자 또는 C1-6알킬, -(C1-6알킬렌)p 기(이때 P는 0 또는 1이고, R6와 R7은 각각 수소원자나 C1-6알킬기이고, 또는 는 5- 또는는 5- 또는 6-원환의 복소환 상기로서 N 원자에 추가하여 -NH-, -O- 또는 -S- 결합을 포함할 수 있다), -(C1-6알킬렌)q-A기 [이때 q는 0 또는 1이고, A는 치환되었거나 비치환된 아릴기), 또는 -(C1-6알킬렌)(C1-6알킬렌)기 (이때 r과 t는 각각 0 또는 1이고, R8과 R9은 각각 수소원자나 C1-6알킬기이고, 또는은 5-또는 6-원환의 복소환상기로서 N 원자에 추가하여 -NH-,-O- 또는 -S- 결합을 포함할 수 있다)[,가[이때 R10은 수소원자 또는 C1-6알킬, 치환되었거나 비치환된 페닐, 또는 모노-나 디 - -C1-6알킬아미노 C1-6알킬기이고, R11과 R12는 각각 수소원자 또는 C1-6알킬기이고, 또는는 5-또는 6-원환의 복소환상기로서 N 원자에 추가하여 -NH-,-O- 또는 -S- 결합을 포함할 수 있다], 또는기[이때 u는 1 또는 2이고, R13과 R14은 각각 수소원자, 또는 C1-6알킬, C2-6알케닐, C2-6알키닐, 아미노, 아미노C1-6알킬 또는 모노-또는 디-C1-6알킬아미노 C1-6알킬기이고, 또는는 5- 또는 6-원환의 복소환상기로서 N 원자에 추가하여 -NH-, -O- 또는 -S- 결합을 포함할수 있다.]
- 제 1항에 있어서, X가 -NH-인 것을 특징으로 하는 화합물.
- 제 1항에 있어서, X가 -O-인 것을 특징으로 하는 화합물.
- 제 1항에 있어서, X가 -S-인 것을 특징으로 하는 화합물.
- 제 2항 내지 제 4항중 어느 하나에 있어서, R이 -(C1-6알킬렌)x (이때 X는 O 또는 1이고, R1과 R2는 독립적으로 수소원자 또는 C1-6알킬기이고, 또는는 5- 또는 6-원환의 복소환상기로서 N원자에 추가하여 -NH-, -O- 또는 -S- 결합을 포함할 수 있다)인 것을 특징으로 하는 화합물.
- 제 5항에 있어서, Z가(이때 W는 -NH- 또는 -CH2- 이고, Q는 =NH, =N-CN, =CH-NO2, =N-SO2NH2, =N-CONH2, =NSO2(아릴), =NSO2(C1-6알킬) 또는 =NSO2(C1-6알킬)이고, R3와 R4는 각각 수소원자, C1-6알킬, C2-6알케닐, 또는 C2-6알키닐이고, 또는는 5- 또는 6-원환의 복소환상기로서 N 원자에 추가하여 -NH-, -O- 또는 -S- 결합을 포함할수 있다)인 것을 특징으로 하는 화합물.
- 제 5항에 있어서, Z가 [이때 G는 =CH- 또는 =N-이고, R5는 수소원자 또는 C1-6알킬, -(C1-6알킬렌)p 기(이때 P는 O 또는 1이고, R6와 R7은 각각 수소원자나 C1-6알킬기이고, 또는는 5- 또는 6-원환의 복소환상기로서 N 원자에 추가하여 -NH-, -O- 또는 -S- 결합을 포함할 수 있다), -(C1-6알킬렌)q-A기 (이때 q는 0 또는 1이고, A는 치환되었거나 비치환된 아릴기), 또는 (C1-6알킬렌)(C1-6알킬렌)t 기 (이때 r과 t는 각각 0 또는 1이고, R8과 R9은 각각 수소원자나 C1-6알킬기이고, 또는은 5-또는 6-원환의 복소환상기로서 N 원자에 추가하여 -NH-, -O- 또는 -S- 결합을 포함할 수 있다)인 것을 특징으로 하는 화합물.
- 제 5항에 있어서, Z가(이때 R10은 수소원자 또는 C1-6알킬, 치환또었거나 비치환된 페닐, 또는 모노-또는 디 - -C1-6알킬아미노 C1-6알킬기이고, R11과 R12는 각각 수소원자 또는 C1-6알킬기이고, 또는는 5-또는 6-원환의 복소환상기로서 N 원자에 추가하여 -NH-, -O- 또는 -S- 결합을 포함할 수 있다)인 것을 특징으로 하는 화합물.
- 제 5항에 있어서 Z가(이때 u는 1 또는 2이고, R13과 R14는 독립적으로 수소원자, 또는 C1-6알킬, C2-6알케닐, C2-6알키닐, 아미노, 아미노C1-6알킬 또는 모노-또는 디- C1-6알킬아미노 C1-6알킬이고, 또는는 5- 또는 6-원환의 복소환상기로서 N 원자에 외에 -NH-, -O- 또는 -S- 결합을 포함할수 있다)인 것을 특징으로 하는 화합물.
- 3-[2-<5-(2-디메틸아미노메틸벤즈이미다졸릴)-메틸티오>에틸] 아미노-4-아미노-1,2,5-티아디아졸-1-옥사이드.
- 1-메틸-5-[2-<5-(2-디메틸아미노메틸벤즈이미다졸릴) 메틸티오>에틸] -1H-1,2,4-트리아졸-3,5-디아민.
- 2-[2-<5-(2-디메틸아미노메틸벤즈이미다졸릴) 메틸티오> 에틸아미노]-5-(3-디메틸아미노벤질)-4-피리미돈.
- 1-니트로-2-메틸아미노-2-[2-<5-(2-(1-피롤리디노메틸)벤즈이미다졸릴)옥시>에틸아미노] 에틸렌.
- 1-니트로-2-메틸아미노-2[2-<5-(2-디메틸아미노메틸벤즈이미다졸릴) 메틸티오> 에틸아미노]에틸렌.
- 1-니트로-2-푸로라트길아미노-2-[2-<5-(2-디메틸아미노메틸벤즈이미다졸릴) 메틸티오> 에틸아미노] 에틸렌.
- 5-[5-(1,3-벤조디옥솔릴)메틸]-2-[3-<5-(2-디메틸아미노메틸벤즈이미다졸릴) 옥시> 푸로필아미노]-4-피리미돈.
- 2-[3-<5-(2-디메틸아미노메틸벤즈이미다졸릴)-옥시> 푸로필아미노]-5-(3-디메틸아미노메틸벤질)-4-피리미돈.
- 2-[2-<5-(2-디메틸아미노메틸벤즈이미다졸릴)-메틸티오>에틸아미노]-5-디메틸아미노메틸-4-피리미돈.
- 2-[2-<5-(2-디메틸아미노메틸벤즈이미다졸릴)메틸티오> 에틸아미노]-5-(3-피롤리디올메틸)-4-피리미돈.
- 3-[2-<5-(2-디메틸아미노메틸벤즈이미다졸릴)메틸티오> 에틸아미노]-6-(3-피리딜메틸-1,2,4-트리아진-5-온.
- {3-[5-<2-(1-피페리디노메틸)벤즈이미다졸릴>옥시]-푸로필}아미노-4-아미노-1,2,5-티아디아졸-1-옥사이드.
- 3-[2-<5-(2--4-디메틸아미노메틸벤즈이미다졸릴)-메틸티오>에틸]아미노-4-메틸아미노-1,2,5-티아디아졸-1-옥사이드.
- 3-[2-<5-(2-디메틸아미노메틸벤즈이미다졸릴)-메틸티오>에틸]아미노-4-(2-푸로피닐아미노)-1,2,5-티아디아졸-1-옥사이드.
- N-설파모일-3-[5-(2-디메틸아미노메틸벤즈이미다졸릴)-메틸티오]푸로피온아미딘.
- 일반식을 갖는 화합물과, 일반식을 갖는 화합물과를 반응시킴을 특징으로 하여 다음 일반식을 갖는 화합물을 제조하는 방법.상기식들에서 R,X,Y,Q,R3및 R4는 청구범위 1항에서 정의한 것과 같고, R30은 C1-6알킬이고 바람직하게는 메틸기이며, A는 -S-또는 -O- 그리고 바람직하게는 -S-이다.
- 일반식인 화합물과, 일반식인 화합물을 반응시킴을 특징으로 하며, 다음 일반식의 화합물을 제조하는 방법.상기 식들에서 R,X,Y,G,R5와 m은 청구범위 제 1항에서 정의한 것과 같고, B는 R40S-(이때 R40은 C1-6알틸이고 바람직하게는 메틸기이다), 또는 니트로아미노(-NH-NO2)기이다.
- 일반식인 화합물과 일반식 R10-NH-NH2인 화합물과를 반응시킴을 특징으로 하여, 다음 일반식의 화합물을 제조하는 방법.상기식 들에서 R,X,Y,R10및 m은 청구범위 제 1항에서 정의한 것과 같고, R50은 C1-6알킬이고 바람직하게는 메틸기이다.
- 일반식인 화합물과, 일반식인 화합물과를 반응시킴을 특징으로 하여, 다음 일반식의 화합물을 제조하는 방법.상기식 들에서 R,X,Y,R13,R14, m 및 u는 청구범위 제 1항에서 정의한 것과 같고, R60은 C1-6알킬기이다.
- 일반식인 화합물과 일반식 H2Q 또는인 화합물을 반응시킴을 특징으로 하여 다음 일반식을 갖는 화합물을 제조하는 방법.상기식 들에서 R,X,Y,Q,R3,R4및 m은 청구범위 제 1항에서 정의한 것과 같고, R70은 C1-6알킬기이다.
- 활성성분으로서 청구범위 제 1항의 화합물과 의학적으로 무방한 그의 염, 수화물 또는 용매화합물을 함유하는 것을 특징으로 하는 항궤양제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57188876A JPS5978171A (ja) | 1982-10-26 | 1982-10-26 | 複素環式化合物 |
JP57-188876 | 1982-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR840006342A true KR840006342A (ko) | 1984-11-29 |
Family
ID=16231416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019830005071A KR840006342A (ko) | 1982-10-26 | 1983-10-26 | 복소환식 화합물 및 그 제법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US4550118A (ko) |
EP (1) | EP0111685A1 (ko) |
JP (1) | JPS5978171A (ko) |
KR (1) | KR840006342A (ko) |
DK (1) | DK491983A (ko) |
ES (1) | ES526731A0 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4644006A (en) * | 1984-06-22 | 1987-02-17 | Bristol-Myers Company | Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity |
US4612309A (en) * | 1984-10-23 | 1986-09-16 | William H. Rorer, Inc. | Antisecretory bicyclic benzo-oxy heterocyclic ethers and thioethers |
SE8604566D0 (sv) * | 1986-10-27 | 1986-10-27 | Haessle Ab | Novel compunds |
GB8820231D0 (en) * | 1988-08-25 | 1988-09-28 | Fujisawa Pharmaceutical Co | New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same |
IE68593B1 (en) * | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
KR20200027533A (ko) | 2017-07-04 | 2020-03-12 | 주식회사 인투셀 | 절단성 링커를 포함하는 화합물 및 이들의 용도 |
WO2022034121A1 (en) | 2020-08-11 | 2022-02-17 | Université De Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3080363A (en) * | 1960-12-27 | 1963-03-05 | Gen Aniline & Film Corp | Sensitizing dyes derived from 2-methyl-6-(2-carbamylethoxy)-benzothiazoles |
US3153033A (en) * | 1961-11-20 | 1964-10-13 | Hoffmann La Roche | Phenylazo formamidines of primary amines |
GB1415910A (en) * | 1973-03-21 | 1975-12-03 | Kyowa Hakko Kogyo Kk | Benzothiazoles |
DE3175201D1 (en) * | 1980-04-30 | 1986-10-02 | Merck & Co Inc | Aminothiadiazoles as gastric secretion inhibitors |
-
1982
- 1982-10-26 JP JP57188876A patent/JPS5978171A/ja active Pending
-
1983
- 1983-10-24 US US06/544,591 patent/US4550118A/en not_active Expired - Fee Related
- 1983-10-25 ES ES526731A patent/ES526731A0/es active Granted
- 1983-10-25 EP EP83110655A patent/EP0111685A1/en not_active Withdrawn
- 1983-10-26 KR KR1019830005071A patent/KR840006342A/ko not_active Application Discontinuation
- 1983-10-26 DK DK491983A patent/DK491983A/da not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DK491983D0 (da) | 1983-10-26 |
ES8504750A1 (es) | 1985-04-16 |
JPS5978171A (ja) | 1984-05-04 |
DK491983A (da) | 1984-04-27 |
US4550118A (en) | 1985-10-29 |
ES526731A0 (es) | 1985-04-16 |
EP0111685A1 (en) | 1984-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR880007478A (ko) | 약제학적 활성 화합물 | |
RU93049322A (ru) | Производные оксадиазинов | |
KR870011129A (ko) | 디스타마이신 a 동족체 및 이의 제조방법 | |
KR840006236A (ko) | 디하이드로 피리딘의 제조방법 | |
KR840006342A (ko) | 복소환식 화합물 및 그 제법 | |
JPS5750989A (en) | Imidazole compound | |
PT77975A (en) | Process for preparing triazole antifungal agents | |
KR910000662A (ko) | 치환된 설포닐디아미드, 이의 제조방법 및 제초제 및 식물 성장 조절제로서의 이의 용도 | |
GB1312493A (en) | Ureidophenylthioureas a process for their preparation and their use as gungicides | |
KR930021635A (ko) | 신규의 살진균성 트리아졸 및 이미다졸 유도체 | |
TW222268B (ko) | ||
EP0094727A3 (en) | Substituted heterocyclyl phenylformamidines, processes for their preparation and their pharmaceutical use | |
ES8404980A1 (es) | Un procedimiento para preparar guanidino-fenilamidinas heterociclicas sustituidas. | |
YU112686A (en) | Process for preparing new amidinic derivatives of 2-substituted 4-phenyl-imidazole | |
DK0504290T3 (da) | Inhibitorer af dihydrofylatreduktase fra Pneumocystis carinii | |
DK308787D0 (da) | Triazol- og imidazolforbindelser | |
DK389683A (da) | Fremgangsmaade til fremstilling af substituerede 1,3,4-benzotriazepiner eller farmaceutisk acceptable syreadditionssalte deraf | |
DK380482A (da) | 1-aryloxy-3-alkylamino-2-propanoler og fremgangsmaade til deres fremstilling | |
ES474282A1 (es) | Un procedimiento para producir un compuesto de piridazinoma. | |
KR860000284A (ko) | 디하이드로피리딘의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |